Pure Biologics S.A. Logo

Pure Biologics S.A.

Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pure Biologics S.A. is a biopharmaceutical company focused on the discovery and development of novel biological drugs and non-systemic therapies. The company utilizes its expertise in antibody and aptamer technologies to develop new therapeutic molecules. Its development portfolio primarily targets immuno-oncology and autoimmune diseases. A key element of its strategy is the focus on creating entirely new biological drugs, as opposed to generic or biosimilar alternatives, positioning itself as an innovator in the biotechnology sector.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 17:54
Share Issue/Capital Change
Rejestracja warrantów subskrypcyjnych imiennych serii C uprawniających do objęc…
Polish 798 bytes
2025-11-14 17:33
Regulatory News Service
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 01.07.2…
Polish 4.1 MB
2025-11-14 17:33
Regulatory News Service
Jednostkowy raport kwartalny Pure Biologics S.A. za 3Q 2025
Polish 1.5 MB
2025-10-27 16:14
Share Issue/Capital Change
Asymilacja akcji serii N Spółki z akcjami znajdującymi się w obrocie na rynku r…
Polish 1.5 KB
2025-10-27 14:05
Registration Form
Rejestracja akcji na okaziciela serii P1 w depozycie papierów wartościowych pro…
Polish 1.1 KB
2025-10-24 18:37
Share Issue/Capital Change
Dopuszczenie i warunkowe wprowadzenie do obrotu na rynku równoległym prowadzony…
Polish 1.5 KB
2025-10-22 11:37
Share Issue/Capital Change
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.2 KB
2025-10-21 17:52
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym…
Polish 1.3 KB
2025-10-21 17:04
Post-Annual General Meeting Information
Treść uchwał podjętych przez NWZ Pure Biologics S.A. w dniu 21.10.2025 r.
Polish 218.5 KB
2025-10-21 17:04
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Pure Biologics S.A…
Polish 775 bytes
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienie Filip Jeleń
Polish 75.8 KB
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienie ACRX Investments Limited
Polish 77.7 KB
2025-10-17 14:29
Major Shareholding Notification
Zawiadomienia akcjonariuszy o zmianie stanu posiadania akcji Spółki - Content (…
Polish 765 bytes
2025-10-15 17:53
Registration Form
Tekst jednolity statutu Spółki
Polish 351.5 KB
2025-10-15 17:53
Registration Form
Rejestracja podwyższenia kapitału zakładowego i zmian statutu Spółki w rejestrz…
Polish 6.1 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pure Biologics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea
365270
Curanex Pharmaceuticals Inc Logo
Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.
United States of America
CURX
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany
CVAC
CureVac N.V. Logo
Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.
United States of America
CVAC
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America
CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea
372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America
CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America
CYCN
CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America
CYTK

Talk to a Data Expert

Have a question? We'll get back to you promptly.